Profiles of women in science: Carmen Sandi, President of the Federation of European Neuroscience Societies.

Eur J Neurosci

The Ernest J. Del Monte Institute for Neuroscience, Department of Neuroscience, School of Medicine and Dentistry, University of Rochester, Rochester, New York.

Published: January 2019

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejn.14271DOI Listing

Publication Analysis

Top Keywords

profiles women
4
women science
4
science carmen
4
carmen sandi
4
sandi president
4
president federation
4
federation european
4
european neuroscience
4
neuroscience societies
4
profiles
1

Similar Publications

Background: To date, 11 DNA polymerase epsilon (POLE) pathogenic variants have been declared "hotspot" mutations. Patients with endometrial cancer (EC) characterized by POLE hotspot mutations (POLEmut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early-stage POLEmut EC, data regarding safety in POLEmut patients with unfavorable characteristics are still under investigation.

View Article and Find Full Text PDF

Meta-analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma.

Int J Gynaecol Obstet

January 2025

Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, People's Republic of China.

Background: In 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups.

Objective: To compare survival of endometrial carcinoma patients with different mutational profiles.

Search Strategy: Studies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases.

View Article and Find Full Text PDF

Endogenous sex hormone levels are associated with the revised Framingham Stroke Risk Profile in postmenopausal women: a longitudinal study in a Swedish cohort.

BMC Endocr Disord

January 2025

Family medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 454, Göteborg, 40530, Sweden.

Background: Endogenous sex hormones in postmenopausal women have been associated with risk of cardiovascular diseases. The aim of this study was to determine the association between endogenous sex hormones and the revised Framingham Stroke Risk Profile (rFSRP) in postmenopausal women.

Methods: This is an observational cross-sectional study on the Vara-Skövde cohort, a Swedish population-based study for longitudinal surveillance of the development and progress of type 2 diabetes and hypertension.

View Article and Find Full Text PDF

Background: We launched the Wako Cohort Study in 2023 to identify individual and socio-environmental factors related to the extension of healthy life expectancy and the reduction of health disparities among community-dwelling adults and to develop health promotion and care prevention strategies. This study profile aims to describe the study design and participants' profile at baseline.

Methods: The Wako Cohort Study is a prospective study of community-dwelling adults aged ≥ 40 years living in Wako City, Saitama Prefecture, Japan.

View Article and Find Full Text PDF

Optimization of Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.

Crit Rev Oncol Hematol

January 2025

Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea. Electronic address:

Background: Despite numerous meta-analyses comparing the efficacy and safety of immunotherapy-based combination therapies, the optimal therapeutic combinations remain unclear. This study aims to evaluate the optimal application of all immunotherapy-based combination therapy for advanced/metastatic renal cell carcinoma, focusing on efficacy and safety.

Methods: We systemically searched the Web of Science, Cochrane Library, and PubMed for studies regarding the first-line immunotherapy-based combination therapy in patients with advanced or metastatic renal cell carcinoma until April 15, 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!